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Summary Thirty-one patients with advanced renal carcinoma or malignant melanoma were treated in the first feasibility study of a-interferon
(Roferon) and the new oral immunomodulating agent, Linomide. Linomide 5 mg or 10 mg p.o. daily was given for 2 weeks; a-interferon was
then added at 3 MU s.c. three times weekty, escalating in each patient by 3 MU per week, if tolerable, up to 12 Mi. The combination was
poorty tolerated with nausea, vomiting, somnolence and myalgia commonly reported. Adverse events accounted for treatment withdrawal in
ten patients and contributed to withdrawal in four other patients. Treatment with Linomide alone in the first 2 weeks led to a significant
increase in white blood cells, neutrophils and platelets. When a-interferon was added. the platelet count decreased significantly over the
following 6 weeks. Nineteen patients had white cell phenotype and function measured. After 2 weeks of 5 mg Linomide, a transient but
significant decrease in the absolute number of activated T-helper cells (CD4+DR-) was observed. No changes in natural killer (NK) cell
number or activity were observed. Twenty-two patients were evaluable for response. One with metastatic renal cell carcinoma had a complete
response and six had stable disease. This study does not support the use of the combination because significant toxicity was seen without the
anticipated immunological benefits.
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Immunotherapv has been used for sexveral years to treat both
advanced renal cell carcinoma and metastatic melanoma.
Recombinant a-interferon as a single agent shoxx-s response rates
of 10-16%7 in renal cancer (Horoszewxicz et al. 1989: Minasian
et al. 1993). with a median response duration of 12.2 months
(Minasian et al. 1993). In a review ofrecombinant a-interferon for
metastatic melanoma. the response rate was 22% and median
response duration 22.6 months (Kirkw-ood. 1991 ). Although phase
II trials of combinations of interferon with other agents including
interleukin 2 (IL-2) and 5-fluorouracil (5 FU) give higher response
rates. these have not proven superior in randomized studies and
further exploration of combinations of immunomodulators is
justified (Oliver. 1994).
Linomide is an oral quinoline-3-carboxamide derixvatix e with
immunomodulatince activitv (Stalhandske et al. 1982). In preclinical
studies. Linomide enhances both the number and actixvitv of natural
killer (NK) cells due to recruitment ofnew target-binding cells from
precursor cells in the bone marrow (Kalland et al. 1985a: Kalland.
1990). An increase in the number of active monocvtes and T-cells
has also been demonstrated w-ith Linomide (Stalhandkse et al. 1986:
Larsson et al. 1987). In clinical pilot studies of patients with solid
tumours (Bergh et al. 1997) and acute myeloid leukaemia patients
after autologous bone marrow transplantation (Bengtsson et al.
1992). increased numbers of circulating phenotxpicafly actixated
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NK cells and monocvtes and increased NK cell function in vitro
have been obser ed x uith Linormide. Linomide also has in xi-xo anti-
tumour activitv against a vaniety of experimental tumours im mice
and rats. includina renal carcinoma and both B16F10 and Harding-
Passes mouse melanomas (Kalland et al. 1985b: Kalland. 1986:
Haminin et al. 1988. 1989). Linomide prolonged survival in mice
transplanted with B16 melanoma. reduced the number of sponta-
neous and ix. induced metastases and suppressed the g!rowth of
established lung metastases (Harmngn et al. 1988). Two minor
responses in renal cancer were seen in the pilot study of Linomide
alone (Bergh et al. 1997).
The combination of Linomide and a-interferon has not previ-
ously been evaluated. Potential svnergsy between Linomide
and a-interferon could be mediated bv interferon independent
enhancement of NK cell cytotoxicitx bv Linormide (Kalland et al.
1985a.) This study u-as designed as a feasibilitv and immunophar-
macology study in patients with advanced malirnant melanoma or
renal cell carcinoma. Its aim was to identifA a tolerable dose of
Linomide when civen in combination with a-interferon. Toxicitx
was assessed. immunological parameters in peripheral blood were
studied in one centre and objective tumour response was evaluated
when appropriate.
PATIENTS AND METHODS
Thirty-one patients were entered in the study wvith histoloaically
xerified malignant melanoma or renal cell carcinoma. Elicibilitv
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criteria included advanced disease not amenable to surgery or
radiotherapy. WHO performance status 0 or 1. age 18-75. no
surgery. hormonal therapy. chemotherapy or radiotherapy within 4
weeks of start of study, and no prior immunotherapy. Written
informed consent from all patients was obtained in accordance with
local ethical committee guidelines. Patients with CNS metastases.
active severe infection, congestive heart disease. severe asthma
andlor chronic bronchitis. previous cardiac disease or other malig-
nancy. raised bilirubin or creatinine. or liver metastases were
specifically excluded. Patients were not allowed concomitant
medication with corticosteroids. H, antagonists. or non-steroidal
anti-inflammatory drugs (NSAIDs) in view of their effects on the
immune system. Ciprofloxacin w'as not permitted because of a
previous reported skin reaction with Linomide. nor acetvlsalicvlic
acid because it competes with Linomide forbinding to albumin.
All patients had full medical history. examination. weight. clin-
ical chemistry and haematology taken before start oftreatment and
at 2. 3. 4. 5. 6 and 8 weeks. Oral Linomide. once a day. was given
alone for the first 2 weeks of therapy. Subcutaneous a-interferon
was then added. three times a week, at a dose of 3 MU and esca-
lating in each patient by 3 MU per week up to 12 MU. iftolerated.
The dose of Linomide was 5 mg in the first cohort of patients and
10 mg in the second. There was no intrapatient escalation of
Linomide. The study plan was to treat ten patients with each dose
of Linomide until they had completed 5 weeks of treatment (2
weeks of Linomide and 3 weeks ofLinomide and a-interferon).
Nineteen patients had blood sampling for immunopharma-
cology twice during the week before starting, therapy. then at 2. 4.
6 and 8 weeks of therapy and 3 weeks after cessation of therapy.
Blood sampling was performed 24 h after the last dose of
Linomide and 48 h after the last dose of interferon. Analyses were
bv FACS-scan flow cvtometry for enumeration of NK-like cells.
monocytes and T-cells. Functional studies of the NK cell activitx
with K562 and Daudi were performed at baseline. 2 and 8 weeks
only (Lesko et al. 1989).
Response was assessed by WHO criteria (Miller et al. 1981)
every 8 weeks bx bidimensional measurement ofpalpable lesions or
imaging. Adxerse events were graded according to WHO cnteria at
each xisit. Patients were initially treated for 8 weeks. but could
continue with treatment ifthere was no disease progression. Time to
Table 1 Patient characteristics (n = 31)
Median age (range) 54 (32-71)
Men:women 21:10
Renal cell carcinoma 24
Melanoma 7
PS 0:1 6:25
Linomide dose 5 mg:10 mg 17:14
Prior nephrectomy 11
Prior surgery 26
Prior radiotherapy 10
Prior chemotherapy 4
Lung metastases 17
Localized recurrence 13
Lymph node/soft tissue sites 12
progression was plotted by the Kaplan-Meier method (Armitage et
al. 1987). The Wilcoxon signed rank sum test (Armitage et al. 1987)
was used to compare numbers of white blood cells (WBCs). differ-
ential counts. platelets. monocytes. T-cefls and number and function
ofNK-like cells at baseline. 2 weeks (Linomide alone) and 8 weeks
(Linomide and interferon) oftreatment.
RESULTS
The characteristics ofthe 31 patients entered are show-n in Table 1.
Two patients were ineligible because of lack ofhistological Xenfi-
cation and an insufficient interval from prior hormonal therapy.
Both are included in the intention to treat and safety analvses. but
not the immunopharmacologv analysis.
Toxicity
Table 2 summarizes toxicity experienced by each patient with
Linomide alone and the change in toxicitr with the addition of
interferon. All patients experienced some kind of toxicity during
treatment. Nausea and vomiting was common with Linomide
alone (61%). but was generally mild. The addition of a-interferon
appeared to enhance this toxicity in 11 out of 27 patients. espe-
cially on the 10-mg Linomide dose. A pattem of fever. rigors.
Table 2 Toxicty
Number of pabents 5 mg Unomide Interferon + 10 mg Interferon +
experiencing adverse event n = 17 5 mg Unomide Unomide 10 mg Unomide
n=14 n=14 n=13
NC W I NC W
WHO grade 1 2 3 1 2 3
Nausea/vomiting 4 5 3 1 3 4 4 2 0 1 8
Fever 2 1 1 0 2 1 1 0 0 2
Anorexia 3 2 3 2 0 2 1 0 1 2
Rigors 2 3 0 0 5 2 0 1 1
Somnolence 3 2 1 1 3 2 2 0 2 2
Diarrhoea 2 2 1 1 1 1 0 0 0
Myalgia 1 2 0 1 2 4 1 1 2 2
Dyspnoea 1 1 0 0 2 1 0 0 1
Arthralgia 1 1 1 0 1 2 2 0 0 4
Paraesthesia 1 1 0 0
1, Number of patients overall with improvement in symptoms on interferon: NC. number of patients overall with no change in symptoms on interferon: W. number
of patients overall with worsening of symptoms on interferon.
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Table 3 Immunopharmacology. Median values (and ranges) for Linomide 5 mg cohort
Weeks from n WBC Neutrophils Lymphocytes Monocytes Platelets CD4+ CD4+DR+ CD14+ CD14,DQG CD56+CD3-
basline
0 14 8.9 6.7 1.1 0.65 380 492.5 74-5 674 35 95.5
(6-11.1) (3.7-8.7) (0.3-2.5) (0.36-1.3) (211-826) (165-2541) (18-518) (284-1774) (9-655) (10-311)
2 13 11.6' 8.75' 1.45 0.7' 446' 410 60' 665 118 54
(7.6-25.1) (5.6-23.6) (0.5-2.4) (0.3-1.8) (226-960) (124-1837) (14-226) (429-1563) (0-365) (7-127)
8 7 6.35 4.8 0.73 0.38 259.5' 670 52 709 137 41
(4.5-9.2) (3.6-6.5) (0.5-1.9) (0.2-1) (100-353) (85-1135) (8-137) (187-818) (6-218) (8-172)
'Significantty different from baseline by Wilcoxon signed rank sum test (P < 0.05).
myalgia and somnolence Aas seen 'Aith Linomide treatment alone.
again worsening with the addition of a-interferon. Of the 27
patients who receixed a-interferon. four experienced thrombo-
cytopenia durinc treatment A-ith a-interferon and Linomide (one
grade 1. three grade 2). During treatment. there was a tendencv to
a fall in haemoglobin lexels. with 17 patients dexeloping some
degree ofanaemia (eight grade 1. eight grade 2 and one grade 3).
There were no treatment-related deaths. One patient died on
study from progressive disease. Nine patients experienced serious
adverse exents possibIx related to Linomide. fi e ofw'hom discon-
tinued Linomide: two with confirmed. exudatixve pericarditis. one
Aith a pleural effusion combined Aith gastrointestinal distur-
bances. one with Guillian-Barre syndrome and the fifth with
lethargy and leg pain. Of the remaining four patients Aho
continued Linomide. two had anaemia. one gastrointestinal distur-
bance and one suspected. non-exudative pericarditis.
Treatment duration and doses of a-interferon
Median treatment duration 'Aas 8 w'eeks. including, 6 weeks of a-
interferon Aith Linomide (range 1-81 Aeeks). Treatment was
discontinued in 13 patients because of disease progression after a
median of 8 w-eeks (rangye 2-19). and in ten patients because of
toxicitv after a median of 7 weeks (rance 1-12). Ofthe remaininc2
eiaht patients. four stopped therapy because of 'completion of
study' (after a median of 33 weeks. range 16-81). and four at
patient's or clinician's request with toxicity as a contributing ex ent
after a median of9 Aeeks treatment (ranoe 2-1 ).
The first cohort of 17 patients received 5 mg of Linomide. Of
these. three did not start a-interferon. txwo because of toxicitx and
one of progressix e disease. After the first eirht patients. the
maximal dose of a-interferon as reduced from 12 to 9 MU
because 12 MU was not tolerated. Oxerall. with 5 mc ofLinomide.
11 patients reached a dose of at least 9 MU of a-interferon three
times a week and Awere treated for a median of 11 weeks.
The second cohort of 14 patients receixed 10 mr of Linomide.
one of'Ahom did not start a-interferon because ofdisease progres-
sion. Of the 13 patients receixing a-interferon. 12 received the
maximal planned dose of 9 MU of a-interferon with a median
treatment duration of 10 w-eeks. Five patients subsequently
required dose reductions of a-interferon and three required dose
reductions of Linomide ow'inc to side effects.
Objective responses
Response w'as ex aluable in 22 patients (13 on 5 mg and nine on
10 mg of Linomide). There was one complete remission after 36
w'eeks treatment in a 57-y-ear-old male with lunc metastases from
renal cell carcinoma in the 10-mg group. He continued treatment
for 56 weeks and stopped because of completion of study. but
progressed 17 'Aeeks later. Six patients (three renal and three
melanoma) had stable disease. 'ith a median time to progression
of 18 weeks (ranae 12-81 weeks). Oxerall median time to progres-
sion was 9 weeks (range 2-81 weeks) for the 5-mg, group and 12
weeks (3-73 weeks) for the 10-mg group.
Immunopharmacology
Nineteen patients had immunopharmacology blood samples tak-en
at baseline (14 in the 5-mg, group. five in the 10-mg group).
Statistical tests were performed on 13 patients between baseline
and 2 weeks and on seven patients between baseline and 8 weeks.
wAith follow-up blood samples in the 5-mg, group only. No such
tests were performed on the 10-mg group ow'ing to limited
numbers (n = 5). Results are show'n in Table 3 for the 5-mgy
Linomide group. There was a statisticallx sicnificant decrease in
the absolute number ofactivated T-helper cells (CD4+DR-) after 2
weeks of 5 ma Linomide. but these changes were not sustained
after 8 weeks of combined treatment. No change in the absolute
and relatix e number of monocvtes (CD14-). activated monocytes
(CD1I4DQ-). or NK cells (CD56-CD3+) A-as notedxxith treatment.
In 12 patients tested. there was no effect on the NK- and
lymphokine-activated killer (LAK) cell activity during treatment.
There was a sianificant increase in the number of WBCs and
neutrophils during the first 2 weeks oftreatment with Linomide in
both dose groups and in monocy-tes in the 5-mg Linomide group.
but this 'as not sustained to 8 w'eeks 'Ahen a-interferon '-as
added. The number of lymphocytes showed a significant decrease
after 8 weeks in the 10-mg Linomide group alone. The number of
platelets increased significantly after 2 Aseeks. but then decreased
significantly after 8 weeks oftreatment in both dose groups.
DISCUSSION
This is the first time a-interferon and Linomide hax-e been used
together. We obserxed no change in the absolute and relatixe
number of NK cells after Linomide alone. nor 'Ahen a-interferon
Aas added. This A-as in contrast to prexious preclinical and clinical
studies (Kalland et al. 1985a: Kalland. 1990: Bengtsson et al.
1992: Bergh et al. 1997). wxhich haxe shown an increase in
absolute and relative numbers of NK cells '-ith an increase in
functional actixitx durinn Linomide treatment. We saw a statisti-
cally significant decrease in the number of actix ated T-cells
(CD4-DR-) after 2 weeks of treatment xxith Linomide alone. not
sustained after 8 wxeeks of combined treatment. In two previous
clinical studies xxith Linomide (Bengtsson et al. 1992: Bergh et al.
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1997). no effect had been seen on activated T-cells. There was no
change in monocytes during treatment in this study compared with
increases in absolute and relative numbers of monocytes previ-
ously reported (Bengtsson et al. 1992; Bergh et al. 1997).
Prechinical studies have denmsed that enhanced NK cell
activity during Linormide treatnent is due to recruitment ofnew cells
from precursor cells in the bone marrow. rather than an increase in
the cytotoxic activity of pre-existing cells (Kalland. 1990). We saw
no change in LAK and NK cell cytotoxicity. The apparent lack of
effect on immunological parameters in this study. particularly NK
cell numbers and activity. may be a result ofthe gross impaiment of
the immunological system in patients with advanced cancer. Indeedk
patients with metastatic disease often have abnormalities in NK cell
function and/or NK cell numbers (Whiteside et al. 1994).
The frequency ofadverse events during the first 2 weeks oftreat-
ment with Linomide alone appears to be the same in both dose
groups. When a-interferon was added. the frequency and severity
of toxicity in each group increased. Combined treatment was
poorly tolerated. with 45% ofthe patients stopping therapy because
of toxicity as a primary (ten patients) or contributing reason (four
clinician/patient request). This is much higher than the 6% with-
drawal rate for toxicity reported with a-interferon alone at doses
greater than 9 MU three times weekly (Minasian et al. 1993). The
similar adverse event profile of Linomide and a-interferon (fever.
fatigue. myalgia. flu-like symptoms. nausea and vomiting) prob-
ably explains the low tolerance ofthe combination in these patients.
In an earlier study. single-agent Linomide 15 mg given twice
weekly achieved two minor responses in renal cell carcinoma
(Bergh et al. 1997). The disappointing observation of only one
response in 22 evaluable patients (4.5%) in the current study makes
it unlikely that the true response rate is over 20% (P = 0.048. one-
sided test). The lack ofadded efficacy with the combination may be
due to the absence ofthe anticipated immunological benefits. partic-
ularly an increase in number and functional activity of NK cells.
This observation. together with the poor tolerability, leads us to
conclude that the combination of a-interferon and Linomide does
not merit further exploration using these doses and this schedule.
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